205 related articles for article (PubMed ID: 35152144)
21. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
22. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Mastoraki A; Schizas D; Vlachou P; Melissaridou NM; Charalampakis N; Fioretzaki R; Kole C; Savvidou O; Vassiliu P; Pikoulis E
Mol Diagn Ther; 2020 Oct; 24(5):557-569. PubMed ID: 32696211
[TBL] [Abstract][Full Text] [Related]
24. Role of HDACs in normal and malignant hematopoiesis.
Wang P; Wang Z; Liu J
Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
[TBL] [Abstract][Full Text] [Related]
25. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
[TBL] [Abstract][Full Text] [Related]
26. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
27. Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.
Schmidt O; Nehls N; Prexler C; von Heyking K; Groll T; Pardon K; Garcia HD; Hensel T; Gürgen D; Henssen AG; Eggert A; Steiger K; Burdach S; Richter GHS
J Exp Clin Cancer Res; 2021 Oct; 40(1):322. PubMed ID: 34654445
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
29. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
30. Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.
Souza BK; da Costa Lopez PL; Menegotto PR; Vieira IA; Kersting N; Abujamra AL; Brunetto AT; Brunetto AL; Gregianin L; de Farias CB; Thiele CJ; Roesler R
Mol Neurobiol; 2018 Sep; 55(9):7242-7258. PubMed ID: 29397557
[TBL] [Abstract][Full Text] [Related]
31. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors.
Lanzi C; Arrighetti N; Pasquali S; Cassinelli G
Biochem Pharmacol; 2023 Sep; 215():115727. PubMed ID: 37541451
[TBL] [Abstract][Full Text] [Related]
32. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
33. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
[TBL] [Abstract][Full Text] [Related]
34. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
35. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
36. A translational perspective on histone acetylation modulators in psychiatric disorders.
Ganguly S; Seth S
Psychopharmacology (Berl); 2018 Jul; 235(7):1867-1873. PubMed ID: 29915963
[TBL] [Abstract][Full Text] [Related]
37. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Stegmaier S; Leuschner I; Aakcha-Rudel E; Münch P; Kazanowska B; Bekassy A; Treuner J; Koscielniak E
Klin Padiatr; 2004; 216(6):315-22. PubMed ID: 15565546
[TBL] [Abstract][Full Text] [Related]
38. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
40. Death by HDAC Inhibition in Synovial Sarcoma Cells.
Laporte AN; Poulin NM; Barrott JJ; Wang XQ; Lorzadeh A; Vander Werff R; Jones KB; Underhill TM; Nielsen TO
Mol Cancer Ther; 2017 Dec; 16(12):2656-2667. PubMed ID: 28878027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
